Union Of India vs Bgp Products Operations Gmbh And Hagene ...

The Supreme Court upheld the Delhi High Court's decision to quash the Notification dated 27.04.2018 issued under Section 26A of the Drugs and Cosmetics Act, 1940, which restricted the manufacture of Oxytocin formulations solely to public sector undertakings. The Court found that the notification was arbitrary and violated the principles of equality and non-discrimination under Article 14 of the Constitution. Consequently, the Court affirmed that the impugned notification did not come into force, allowing private sector companies to continue manufacturing Oxytocin for domestic use.